LRRK2 and Parkinson disease: In contrast, in heterozygous G2019S LRRK2 PD patient-derived LCLs, treatment with EB-42168 partially reduced LRRK2 pSer935 phosphorylation, ~30 and 40% with 10 and 100 nM, respectively (Fig. 7b, d), presumably due to a lack of sensitivity on WT LRRK2 which accounts for ~50% of the total pSer935 signal in heterozygous cells.